AU2004209985B2 - Methods for treating, preventing and detecting Helicobacter infection - Google Patents

Methods for treating, preventing and detecting Helicobacter infection Download PDF

Info

Publication number: AU2004209985B2
Authority: AU; Australia
Prior art keywords: cerdo; helicobacter; subject; infection; immunogen
Prior art date: 2003-02-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

AU2004209985A

Other languages

English (en)

Other versions

AU2004209985A1 (en

Inventor

Kathyrn Eaton

John Ellis

Joel Flores

George Krakowka

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cerebus Biologicals Inc

Original Assignee

Cerebus Biologicals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-03

Filing date

2004-02-02

Publication date

2008-09-18

2004-02-02 Application filed by Cerebus Biologicals Inc filed Critical Cerebus Biologicals Inc

2004-08-19 Publication of AU2004209985A1 publication Critical patent/AU2004209985A1/en

2008-09-18 Application granted granted Critical

2008-09-18 Publication of AU2004209985B2 publication Critical patent/AU2004209985B2/en

2024-02-02 Anticipated expiration legal-status Critical

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 83
206010019375 Helicobacter infections Diseases 0.000 title claims description 25
241001202111 Cerambyx cerdo Species 0.000 claims description 146
241000589989 Helicobacter Species 0.000 claims description 58
239000000203 mixture Substances 0.000 claims description 57
230000002163 immunogen Effects 0.000 claims description 52
239000006166 lysate Substances 0.000 claims description 47
239000002671 adjuvant Substances 0.000 claims description 28
208000015181 infectious disease Diseases 0.000 claims description 26
241000894006 Bacteria Species 0.000 claims description 24
239000012472 biological sample Substances 0.000 claims description 21
230000002797 proteolythic effect Effects 0.000 claims description 20
210000002966 serum Anatomy 0.000 claims description 16
230000029087 digestion Effects 0.000 claims description 14
102000004190 Enzymes Human genes 0.000 claims description 11
108090000790 Enzymes Proteins 0.000 claims description 11
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 10
239000000523 sample Substances 0.000 claims description 10
239000000427 antigen Substances 0.000 description 67
108091007433 antigens Proteins 0.000 description 66
102000036639 antigens Human genes 0.000 description 66
108090000623 proteins and genes Proteins 0.000 description 57
235000018102 proteins Nutrition 0.000 description 40
102000004169 proteins and genes Human genes 0.000 description 40
230000008859 change Effects 0.000 description 32
108090000765 processed proteins & peptides Proteins 0.000 description 31
102000004196 processed proteins & peptides Human genes 0.000 description 30
208000025865 Ulcer Diseases 0.000 description 28
229960005486 vaccine Drugs 0.000 description 28
210000004027 cell Anatomy 0.000 description 24
229920001184 polypeptide Polymers 0.000 description 24
238000002965 ELISA Methods 0.000 description 20
150000001413 amino acids Chemical group 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
108091026890 Coding region Proteins 0.000 description 19
108020004414 DNA Proteins 0.000 description 19
238000002255 vaccination Methods 0.000 description 19
108091005804 Peptidases Proteins 0.000 description 17
239000004365 Protease Substances 0.000 description 17
241000282898 Sus scrofa Species 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 17
230000001580 bacterial effect Effects 0.000 description 17
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 16
229940024606 amino acid Drugs 0.000 description 16
239000012634 fragment Substances 0.000 description 16
235000019419 proteases Nutrition 0.000 description 16
230000002496 gastric effect Effects 0.000 description 15
230000027455 binding Effects 0.000 description 14
239000000499 gel Substances 0.000 description 14
210000002784 stomach Anatomy 0.000 description 14
238000012360 testing method Methods 0.000 description 14
208000007882 Gastritis Diseases 0.000 description 13
241000282887 Suidae Species 0.000 description 13
201000010099 disease Diseases 0.000 description 13
238000009472 formulation Methods 0.000 description 13
230000028993 immune response Effects 0.000 description 12
150000007523 nucleic acids Chemical class 0.000 description 12
231100000397 ulcer Toxicity 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000000463 material Substances 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
238000010790 dilution Methods 0.000 description 10
239000012895 dilution Substances 0.000 description 10
230000000694 effects Effects 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
210000001156 gastric mucosa Anatomy 0.000 description 10
239000012528 membrane Substances 0.000 description 10
238000009021 pre-vaccination Methods 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
108010046334 Urease Proteins 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
108020004707 nucleic acids Proteins 0.000 description 9
102000039446 nucleic acids Human genes 0.000 description 9
101100476480 Mus musculus S100a8 gene Proteins 0.000 description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
238000003556 assay Methods 0.000 description 8
210000002318 cardia Anatomy 0.000 description 8
230000003628 erosive effect Effects 0.000 description 8
210000004877 mucosa Anatomy 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
230000004044 response Effects 0.000 description 8
239000007790 solid phase Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
241000282412 Homo Species 0.000 description 7
108060003951 Immunoglobulin Proteins 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
102000018358 immunoglobulin Human genes 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
238000003786 synthesis reaction Methods 0.000 description 7
239000013598 vector Substances 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
241000590002 Helicobacter pylori Species 0.000 description 6
230000005875 antibody response Effects 0.000 description 6
-1 aromatic amino acids Chemical class 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
229940037467 helicobacter pylori Drugs 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
239000003446 ligand Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000013519 translation Methods 0.000 description 6
230000014616 translation Effects 0.000 description 6
238000011282 treatment Methods 0.000 description 6
230000036269 ulceration Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
238000012286 ELISA Assay Methods 0.000 description 5
208000007107 Stomach Ulcer Diseases 0.000 description 5
206010046865 Vaccinia virus infection Diseases 0.000 description 5
241000700605 Viruses Species 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000011324 bead Substances 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000006870 function Effects 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
230000003118 histopathologic effect Effects 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
244000052769 pathogen Species 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
108091033319 polynucleotide Proteins 0.000 description 5
102000040430 polynucleotide Human genes 0.000 description 5
239000002157 polynucleotide Substances 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000000758 substrate Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
208000007089 vaccinia Diseases 0.000 description 5
238000005406 washing Methods 0.000 description 5
238000001262 western blot Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 4
102000016938 Catalase Human genes 0.000 description 4
108010053835 Catalase Proteins 0.000 description 4
102000009016 Cholera Toxin Human genes 0.000 description 4
108010049048 Cholera Toxin Proteins 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
101710112752 Cytotoxin Proteins 0.000 description 4
108010040721 Flagellin Proteins 0.000 description 4
208000012895 Gastric disease Diseases 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 4
238000007792 addition Methods 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000003484 anatomy Anatomy 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
231100000599 cytotoxic agent Toxicity 0.000 description 4
239000002619 cytotoxin Substances 0.000 description 4
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
210000001198 duodenum Anatomy 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
239000002243 precursor Substances 0.000 description 4
150000003839 salts Chemical group 0.000 description 4
229940031439 squalene Drugs 0.000 description 4
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010077805 Bacterial Proteins Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
241000283707 Capra Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
102000057297 Pepsin A Human genes 0.000 description 3
108090000284 Pepsin A Proteins 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
239000004599 antimicrobial Substances 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
239000000975 dye Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
108020001507 fusion proteins Proteins 0.000 description 3
102000037865 fusion proteins Human genes 0.000 description 3
230000000762 glandular Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000016784 immunoglobulin production Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
210000003622 mature neutrocyte Anatomy 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
210000003097 mucus Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229940111202 pepsin Drugs 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000000047 product Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
210000001187 pylorus Anatomy 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000011084 recovery Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
241000894007 species Species 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000012546 transfer Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
208000004300 Atrophic Gastritis Diseases 0.000 description 2
241000271566 Aves Species 0.000 description 2
102000006303 Chaperonin 60 Human genes 0.000 description 2
108010058432 Chaperonin 60 Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
208000036495 Gastritis atrophic Diseases 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
241001490623 Helicobacter suis Species 0.000 description 2
108010025076 Holoenzymes Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
208000008469 Peptic Ulcer Diseases 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
108010034949 Thyroglobulin Proteins 0.000 description 2
102000009843 Thyroglobulin Human genes 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
239000012491 analyte Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
229940009098 aspartate Drugs 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
239000002585 base Substances 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
208000016644 chronic atrophic gastritis Diseases 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
238000002224 dissection Methods 0.000 description 2
208000000718 duodenal ulcer Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000003325 follicular Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
229930195712 glutamate Natural products 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
230000002962 histologic effect Effects 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
210000003405 ileum Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
238000002955 isolation Methods 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000012160 loading buffer Substances 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
229960000282 metronidazole Drugs 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
239000008267 milk Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000002850 nasal mucosa Anatomy 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
229960000381 omeprazole Drugs 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
229940031626 subunit vaccine Drugs 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
229960002175 thyroglobulin Drugs 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
239000004474 valine Substances 0.000 description 2
YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
OZDWKEFYXKSYIZ-UHFFFAOYSA-N 2-[5-(aminomethyl)-2,4-dioxo-1H-pyrimidin-6-yl]acetic acid Chemical compound C(=O)(O)CC1=C(C(NC(N1)=O)=O)CN OZDWKEFYXKSYIZ-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
UDZRZGNQQSUDNP-UHFFFAOYSA-N 6-(aminomethyl)-5-methoxy-2-sulfanylidene-1H-pyrimidin-4-one Chemical compound COC=1C(NC(NC=1CN)=S)=O UDZRZGNQQSUDNP-UHFFFAOYSA-N 0.000 description 1
HSPHKCOAUOJLIO-UHFFFAOYSA-N 6-(aziridin-1-ylamino)-1h-pyrimidin-2-one Chemical compound N1C(=O)N=CC=C1NN1CC1 HSPHKCOAUOJLIO-UHFFFAOYSA-N 0.000 description 1
CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
SWJYOKZMYFJUOY-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7h-purin-8-one Chemical compound OC1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SWJYOKZMYFJUOY-KQYNXXCUSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
244000105975 Antidesma platyphyllum Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
208000034309 Bacterial disease carrier Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241000251556 Chordata Species 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
241000272496 Galliformes Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010017788 Gastric haemorrhage Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
102000002812 Heat-Shock Proteins Human genes 0.000 description 1
108010004889 Heat-Shock Proteins Proteins 0.000 description 1
241001495142 Helicobacter heilmannii Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
201000003791 MALT lymphoma Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
102000005348 Neuraminidase Human genes 0.000 description 1
108010006232 Neuraminidase Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
UYCAGRPOUWSBIQ-WOYAITHZSA-N [(1s)-1-carboxy-4-(diaminomethylideneamino)butyl]azanium;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound OC(=O)[C@@H]1CCC(=O)N1.OC(=O)[C@@H](N)CCCN=C(N)N UYCAGRPOUWSBIQ-WOYAITHZSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229940024545 aluminum hydroxide Drugs 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
238000011203 antimicrobial therapy Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
WXNRAKRZUCLRBP-UHFFFAOYSA-N avridine Chemical compound CCCCCCCCCCCCCCCCCCN(CCCN(CCO)CCO)CCCCCCCCCCCCCCCCCC WXNRAKRZUCLRBP-UHFFFAOYSA-N 0.000 description 1
229950010555 avridine Drugs 0.000 description 1
210000001099 axilla Anatomy 0.000 description 1
201000001579 bacterial gastritis Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
229960000782 bismuth subsalicylate Drugs 0.000 description 1
ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
229950004398 broxuridine Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001886 ciliary effect Effects 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
229960002626 clarithromycin Drugs 0.000 description 1
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
PBKSAWGZZXKEBJ-UHFFFAOYSA-N cyclopenta-1,3-diene;4-cyclopenta-2,4-dien-1-ylphenol;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.C1=CC(O)=CC=C1[C-]1C=CC=C1 PBKSAWGZZXKEBJ-UHFFFAOYSA-N 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
230000006837 decompression Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002183 duodenal effect Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
210000003495 flagella Anatomy 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
201000006585 gastric adenocarcinoma Diseases 0.000 description 1
208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 1
244000000075 gastric pathogen Species 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000004554 glutamine Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
235000009424 haa Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
210000001822 immobilized cell Anatomy 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
230000001759 immunoprophylactic effect Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000037427 ion transport Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
244000144972 livestock Species 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
DJLUSNAYRNFVSM-UHFFFAOYSA-N methyl 2-(2,4-dioxo-1h-pyrimidin-5-yl)acetate Chemical compound COC(=O)CC1=CNC(=O)NC1=O DJLUSNAYRNFVSM-UHFFFAOYSA-N 0.000 description 1
IZAGSTRIDUNNOY-UHFFFAOYSA-N methyl 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetate Chemical compound COC(=O)COC1=CNC(=O)NC1=O IZAGSTRIDUNNOY-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
238000009629 microbiological culture Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
229960000564 nitrofurantoin Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
101150004354 npp-22 gene Proteins 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000007793 ph indicator Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000020978 protein processing Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000035322 succinylation Effects 0.000 description 1
238000010613 succinylation reaction Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000006150 trypticase soy agar Substances 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
101150061086 ureB gene Proteins 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
101150080234 vacA gene Proteins 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)

AU2004209985A 2003-02-03 2004-02-02 Methods for treating, preventing and detecting Helicobacter infection Expired AU2004209985B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US44419003P	2003-02-03	2003-02-03
US60/444,190		2003-02-03
US51815603P	2003-11-07	2003-11-07
US60/518,156		2003-11-07
PCT/US2004/002867 WO2004069184A2 (en)	2003-02-03	2004-02-02	Methods for treating, preventing and detecting helicobacter infection

Publications (2)

Publication Number	Publication Date
AU2004209985A1 AU2004209985A1 (en)	2004-08-19
AU2004209985B2 true AU2004209985B2 (en)	2008-09-18

Family

ID=32853359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2004209985A Expired AU2004209985B2 (en)	2003-02-03	2004-02-02	Methods for treating, preventing and detecting Helicobacter infection

Country Status (11)

Country	Link
US (1)	US20070026018A1 (es)
EP (1)	EP1599164B1 (es)
AU (1)	AU2004209985B2 (es)
BR (1)	BRPI0407207A (es)
CA (1)	CA2514576C (es)
DK (1)	DK1599164T3 (es)
HU (1)	HUE026171T2 (es)
MX (1)	MXPA05008252A (es)
RU (1)	RU2005127573A (es)
UA (1)	UA84284C2 (es)
WO (1)	WO2004069184A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060029617A1 (en) *	1997-10-03	2006-02-09	Charreyre Catherine E	Porcine circovirus and Helicobacter combination vaccines and methods of use
CN101048181A (zh)	2004-08-13	2007-10-03	巴里·J·马沙尔	细菌递送系统
US8029777B2 (en)	2004-08-13	2011-10-04	Marshall Barry J	Helicobacter system and uses thereof
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en)	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
RU2007135028A (ru) *	2005-02-23	2009-03-27	Сирибас Байолоджикалз, Инк. (Us)	Инфекция helicobacter у свиней
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
CA2612271A1 (en)	2005-06-16	2006-12-21	Universiteit Gent	Vaccines for immunization against helicobacter
US7790143B2 (en)	2005-06-16	2010-09-07	Universiteit Gent	Vaccines for immunization against helicobacter
MX356667B (es)	2005-12-29	2018-06-08	Boehringer Ingelheim Vetmedica Inc	Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
BRPI0620859A2 (pt)	2005-12-29	2011-11-22	Boehringer Ingelheim Vetmedica, Inc.	vacina de combinação multivalente contra pcv2
US20100074846A1 (en) *	2006-03-17	2010-03-25	Ellis John A	Campylobacter Vaccines and Methods of use
WO2008085549A2 (en) *	2006-07-28	2008-07-17	Board Of Regents Of The University Of Texas System	Compositions and methods for stimulation of lung innate immunity
EP2101815A4 (en)	2006-12-11	2010-10-06	Boehringer Ingelheim Vetmed	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
DK2094872T4 (da)	2006-12-15	2020-05-18	Boehringer Ingelheim Animal Health Usa Inc	Behandling af anti-PCV2-antistofseropositive svin med PCV2-antigen
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009126356A2 (en)	2008-01-23	2009-10-15	Boehringer Ingelheim Vetmedica, Inc.	Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US20110105383A1 (en) *	2008-09-10	2011-05-05	Magnus Hook	Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
BRPI1009842B8 (pt)	2009-03-25	2021-05-25	Univ Texas	uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
MX373884B (es)	2013-10-02	2020-03-26	Boehringer Ingelheim Animal Health Usa Inc	Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
US10286065B2 (en)	2014-09-19	2019-05-14	Board Of Regents, The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BR112018012033A2 (pt)	2015-12-14	2018-12-04	Max Planck Gesellschaft	composição imunogênica e método para detectar infecção por h. pylori em um sujeito
EP3272354A1 (en)	2016-07-20	2018-01-24	Technische Universität München	Agents and methods for the prevention or treatment of h. pylori infections
CN111793137A (zh) *	2019-12-12	2020-10-20	南京蛋球球生物医学技术合伙企业(有限合伙)	一种Hp四价抗原及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6130059A (en) *	1992-03-02	2000-10-10	Covacci; Antonello	Helicobacter pylori proteins useful for vaccines and diagnostics
JP2001514486A (ja) *	1997-01-24	2001-09-11	コルテクス（ユーケイ）リミティッド	エイチ．ピロリ抗原
US20020107368A1 (en) *	2000-12-07	2002-08-08	Jing-Hui Tian	Helicobacter proteins, gene sequences and uses thereof

2004
- 2004-02-02 MX MXPA05008252A patent/MXPA05008252A/es active IP Right Grant
- 2004-02-02 AU AU2004209985A patent/AU2004209985B2/en not_active Expired
- 2004-02-02 CA CA2514576A patent/CA2514576C/en not_active Expired - Lifetime
- 2004-02-02 EP EP04707401.8A patent/EP1599164B1/en not_active Expired - Lifetime
- 2004-02-02 WO PCT/US2004/002867 patent/WO2004069184A2/en not_active Ceased
- 2004-02-02 UA UAA200508503A patent/UA84284C2/ru unknown
- 2004-02-02 BR BR0407207-3A patent/BRPI0407207A/pt not_active Application Discontinuation
- 2004-02-02 RU RU2005127573/15A patent/RU2005127573A/ru unknown
- 2004-02-02 HU HUE04707401A patent/HUE026171T2/en unknown
- 2004-02-02 DK DK04707401.8T patent/DK1599164T3/en active
2005
- 2005-08-03 US US11/196,722 patent/US20070026018A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2005127573A (ru)	2006-01-27
CA2514576A1 (en)	2004-08-19
WO2004069184A2 (en)	2004-08-19
UA84284C2 (ru)	2008-10-10
HUE026171T2 (en)	2016-05-30
CA2514576C (en)	2015-07-21
DK1599164T3 (en)	2015-04-27
EP1599164A4 (en)	2007-08-01
WO2004069184A3 (en)	2006-12-21
BRPI0407207A (pt)	2006-01-24
EP1599164B1 (en)	2015-04-08
AU2004209985A1 (en)	2004-08-19
US20070026018A1 (en)	2007-02-01
MXPA05008252A (es)	2006-05-22
EP1599164A2 (en)	2005-11-30

Publication	Publication Date	Title
AU2004209985B2 (en)	2008-09-18	Methods for treating, preventing and detecting Helicobacter infection
US10261092B2 (en)	2019-04-16	Cross-reactive determinants and methods for their identification
EP0614488A1 (en)	1994-09-14	Recombinant vaccine against lyme disease
AU2018368580B2 (en)	2024-11-14	Vaccine compositions for use against digital dermatitis in a mammal
US7749512B2 (en)	2010-07-06	Porcine Helicobacter infection
EP1860951B1 (en)	2012-06-06	Animal model for porcine helicobacter infection
JPH11505267A (ja)	1999-05-18	ヘリコバクター・ピロリの新規膜タンパクｐ７６
JPH10511116A (ja)	1998-10-27	ヘリコバクター・ピロリの新規膜タンパク
US20100074846A1 (en)	2010-03-25	Campylobacter Vaccines and Methods of use
HK1149770B (en)	2016-02-19	Compositions, methods and kits

Legal Events

Date	Code	Title	Description
2009-01-22	FGA	Letters patent sealed or granted (standard patent)
2024-02-22	MK14	Patent ceased section 143(a) (annual fees not paid) or expired